



VITAMIN D:

Moving Toward Evidence-based Decision Making in Primary Care Conference & Webinar



December 2–3, 2014

NIH, Bethesda, MD

AGENDA

DAY 1 — TUESDAY, DECEMBER 2

7:00 A.M. REGISTRATION

8:00 A.M. Welcome and Rationale for Conference
Conference Chair: *Clifford Rosen, M.D.* — Maine Medical Center Research Institute

SESSION 1: THE CHALLENGES—HOW DO WE EVALUATE AND APPLY EVIDENCE FOR PRIMARY CARE DECISION MAKING?

8:10 A.M. Principles for Evaluating Evidence
Barry S. Kramer, M.D., M.P.H. — National Cancer Institute (NCI), National Institutes of Health (NIH)

8:40 A.M. Translating Evidence into Guidelines
Victor M. Montori, M.D. — Mayo Clinic

9:10 A.M. Revised Criteria for National Guidelines Clearinghouse
Mary Nix, M.S. — Agency for Healthcare Research and Quality

9:30 A.M. BREAK

9:45 A.M. Development of Endocrine Society Guidelines
Michael F. Holick, M.D., Ph.D. — Boston University School of Medicine

10:15 A.M. Applying Systematic Reviews to Dietary Reference Intakes: Vitamin D as a Case Study
Patsy M. Brannon, Ph.D., M.S. — Cornell University

10:45 A.M. U.S. Preventive Services Task Force: Screening for Vitamin D Deficiency
Michael L. LeFevre, M.D., M.S.P.H. — University of Missouri

11:15 A.M. Panel: Perspectives on Evaluating Evidence in Primary Care Context
Moderator: *Paul M. Coates, Ph.D.* — Office of Dietary Supplements (ODS), NIH

- *Robert P. Heaney, M.D.* — Creighton University
- *Gordon Guyatt, M.D., M.Sc., F.R.C.P.C., O.C.* — McMaster University
- *Edward L. Giovannucci, M.D., Sc.D.* — Harvard School of Public Health
- *Roger Bouillon, M.D., Ph.D., F.R.C.P.* — KU Leuven, Belgium

Open Discussion: Panel and Audience

12:15 P.M. LUNCH (ON YOUR OWN)



SESSION 2: WHAT IS THE VIEW FROM THE FRONT LINES?

1:30 P.M. The Vitamin D Landscape
Clifford Rosen, M.D. — Maine Medical Center Research Institute

1:45 P.M. Panel: What Is the Vitamin D Experience?
Moderator: *Clifford Rosen, M.D.* — Maine Medical Center Research Institute

- *Ravi I. Thadhani — M.D., M.P.H.* — Harvard University and Massachusetts General Hospital
- *Peter S. Millard, M.D., Ph.D.* — Seaport Community Health Center
- *Sylvia B. Rowe, M.A.* — SR Strategy, LLC.

Open Discussion: Panel and Audience

SESSION 3: THE UNCERTAINTIES—HOW DO WE THINK ABOUT RISK OF NUTRITIONAL INADEQUACY?

2:15 P.M. Requirement Distributions and Clinical Practice
Alicia L. Carriquiry, Ph.D., M.Sc. — Iowa State University

2:45 P.M. BREAK

3:00 P.M. Groups at Risk: Is Lower Serum 25(OH)D Always a Concern?
Bonny Specker, Ph.D. — South Dakota State University

3:30 P.M. African American Case Study: Serum 25(OH)D and Bone Health
John F. Aloia, M.D. — Winthrop University Hospital and SUNY Stony Brook

4:00 P.M. African American Case Studies: Genetic Variants

- **Perspective 1**
Ravi I. Thadhani, M.D., M.P.H. — Harvard University and Massachusetts General Hospital
- **Perspective 2**
Roger Bouillon, M.D., Ph.D., F.R.C.P. — KU Leuven, Belgium

Open Discussion: Panel and Audience

5:00 P.M. ADJOURN

DAY 2 — WEDNESDAY, DECEMBER 3

SESSION 4: THE UNCERTAINTIES—WHAT DO WE KNOW ABOUT VITAMIN D INTAKE AND SUPPLEMENT USE?

7:30 A.M. REGISTRATION

8:00 A.M. Current Exposure to Vitamin D: Food, Food Fortification, and Supplements
Valerie Tarasuk, Ph.D. — University of Toronto

8:30 A.M. Changes in Serum 25(OH)D Concentrations with Amount and Nature of Intake
Sue A. Shapses, Ph.D., R.D. — Rutgers University

9:00 A.M. Possible Adverse Consequences of Higher Vitamin D Status: Emerging Evidence from Observational Studies
Demetrius Albanes, M.D. — NCI, NIH

9:30 A.M. Sessions 3 & 4: Joint Panel Discussion—Balancing Risk and Intervention
Moderator: *Susan T. Mayne, Ph.D. — Yale School of Public Health*

- *Valerie Tarasuk, Ph.D. — University of Toronto*
- *Sue A. Shapses, Ph.D., R.D. — Rutgers University*
- *Demetrius Albanes, M.D. — NCI, NIH*
- *Bonny Specker, Ph.D. — South Dakota State University*
- *John F. Aloia, M.D. — Winthrop University Hospital and SUNY Stony Brook*
- *Ravi I. Thadhani, M.D., M.P.H. — Harvard University and Massachusetts General Hospital*
- *Roger Bouillon, M.D., Ph.D., F.R.C.P. — KU Leuven, Belgium*

Open Discussion: Panel and Audience

10:00 A.M. BREAK

SESSION 5: THE UNCERTAINTIES—WHAT ARE ISSUES SURROUNDING LABORATORY MEASUREMENT OF SERUM 25(OH)D?

10:15 A.M. Measurement of 25(OH)D: Perspective from the Clinical Lab
Andrew Hoofnagle, M.D., Ph.D. — University of Washington

10:45 A.M. Panel: What Do These Methodology Issues Mean for Clinical Practice?
Moderator: *Paul M. Coates, Ph.D. — ODS, NIH*

- *J. Sanford Schwartz, M.D. — Wharton University of Pennsylvania*
- *John F. Aloia, M.D. — Winthrop University Hospital and SUNY Stony Brook*
- *Ian S. Young, Ph.D. — Queen's University Belfast and Centre for Public Health*

Open Discussion: Panel and Audience

SESSION 6: WHAT CAN WE SAY ABOUT TRANSLATING EVIDENCE INTO CLINICAL PRACTICE AND THE RELATED RESEARCH NEEDS?

- 11:15 A.M. Panel Discussion: What Did We Hear and What Are the Next Steps?**
Moderator: *Clifford Rosen, M.D.* — Maine Medical Center Research Institute
- *Bess Dawson-Hughes, M.D.* — Tufts University
 - *Victor M. Montori, M.D.* — Mayo Clinic
 - *Michael L. LeFevre, M.D., M.S.P.H.* — University of Missouri

Open Discussion: Panel and Audience

12:00 NOON CLOSING COMMENTS AND ADJOURN